Biotech and Pharmaceuticals
Chipotle chases the protein craze with new menu items — including meat in a cup
A Chipotle restaurant in San Francisco, California, US, on Friday, Jan. 31, 2025. David Paul Morris | Bloomberg | Getty Images Chipotle Mexican Grill is entering the snack business. The fast-casual giant announced Thursday it will roll out its first-ever “High Protein Menu” later this month, featuring grab-and-go protein cups. Starting Tuesday, customers in the […]
Read More
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial. The company also said it has filed for Food and Drug Administration approval of the daily […]
Read More
Medical supply firm Medline set to debut after biggest IPO of 2025
U.S. medical supplies giant Medline is set to debut on the Nasdaq on Wednesday after the biggest initial public offering of the year. The private equity-owned company priced at $29 per share on Tuesday, raising $6.26 billion in an upsized offering that finishes off a strong year for new listings and bolsters optimism about the […]
Read More
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1 pills for obesity are closer than ever. 2026 is likely the year that two new oral weight loss […]
Read More
What Trump’s reclassification of pot and CBD could mean for seniors, research and stocks
Tarek Adieh, of Tampa, Florida, looks at cannabis flower from wholesaler Dep Kings at CHAMPS Trade Show at the Palmer Events Center Thursday, Sept. 11, 2025. Jay Jannar | Hearst Newspapers | Getty Images President Donald Trump is expected to sign an executive order this week that would broadly expand access to cannabis. Industry advocates, […]
Read More
Pfizer’s modest 2026 outlook shows its big investments will take time to pay off
Smith Collection | Archive Photos | Getty Images Pfizer on Tuesday forecast modest 2026 guidance as it looks to longer-term investments in its pipeline to counter waning Covid product sales and declines from older drugs. Those hurdles aren’t surprising or new for Pfizer, which has seen a dramatic decline in Covid vaccine and antiviral sales […]
Read More
Europe’s best-performing stock is up 1,400% this year. Here’s what’s next
Key Points Abivax shares are up more than 1,400% year to date as investors are optimistic about the prospects of its treatment for ulcerative colitis. “We are certainly excited about the work we are doing, and we’ve been greeted again by the medical community as becoming possibly this next standard of care in ulcerative colitis,” […]
Read More
Healthy Returns: FDA may add its strongest safety warning to Covid vaccines. Here’s what to know
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food and Drug Administration may add its strongest safety warning to Covid shots – marking another major shift in vaccine oversight. It could also expand a […]
Read More
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]
Read More
Eli Lilly’s next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Thursday said its next-generation obesity drug delivered strong weight loss and reduced knee arthritis pain in a late-stage study, clearing the first of several upcoming trials on the weekly injection. The […]
Read More